Jane Street’s ArriVent BioPharma AVBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$407K Sell
17,658
-85,597
-83% -$1.93M ﹤0.01% 8523
2025
Q4
$2.08M Buy
+103,255
New +$2.15M ﹤0.01% 4742
2024
Q4
Sell
-10,626
Closed -$250K 10784
2024
Q3
$250K Sell
10,626
-4,707
-31% -$107K ﹤0.01% 8325
2024
Q2
$284K Sell
15,333
-21,626
-59% -$386K ﹤0.01% 7881
2024
Q1
$660K Buy
+36,959
New +$745K ﹤0.01% 6169

Other funds holding AVBP

Jane Street's AVBP Position: Q1 2026 in Review

Jane Street reduced its ArriVent BioPharma (AVBP) stake by 83% in Q1 2026, selling an estimated $1.93M and leaving 17,658 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #8523.

Jane Street first reported a position in AVBP in Q1 2024 and has held it in 5 quarters since. The position peaked at $2.08M in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Jane Street held 17,658 shares of ArriVent BioPharma worth $407K as of Q1 2026.
  • Jane Street sold 85,597 ArriVent BioPharma shares in Q1 2026, an estimated $1.93M.
  • ArriVent BioPharma made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #8523 holding.
  • Jane Street first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 5 quarters since.
  • Jane Street's ArriVent BioPharma position peaked at $2.08M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.